

## The management of CML: current treatment paradigms and future perspectives

An educational day for European fellows on behalf of EUTOS for CML  
 Policlinico Universitario, Naples  
 17 – 18 May 2010

### Session 1: First-line treatment approaches in CML – Monday May 17th

14.00	Introduction and objectives	F. Pane
14.10	The molecular pathogenesis of CML: chronic phase, genomic instability and transformation to blast phase	G. Saglio
14.35	First line treatment of CML with imatinib: the 8-year follow-up perspective	A. Hochhaus
15.05	Can we improve response of first line treatment of CML? Dose escalation, combination with IFN or other drugs	G. Rosti
<b>15.35</b>	<b>REFRESHMENT BREAK</b>	
15.55	Living with CML: practical management and long-term treatment effects	L. Luciano
16.15	Management of special CML populations: Pregnant, paediatric and elderly patients	D. Niederwieser
16.35	Q & A session	Panel
16.50	Clinical case presentations 1 & 2	TBD*
17.10	Session wrap-up	F. Pane
<b>17.15</b>	<b>SESSION CLOSE</b>	

### Session 2: Prognostic factors for treatment response in CML – Tuesday May 18th

08.30	Welcome back	F. Pane
08.35	Advanced methods of disease monitoring: BCR-ABL quantitation, mutation detection and imatinib blood level testing	F.X. Mahon
08.55	The clinical value of complete molecular response and of mutation detection	F. Pane
09.15	Cellular and molecular mechanisms of imatinib resistance	G. Martinelli
09.35	Stem cell transplantation in CML treatment, and accelerated and blast phase management	S. Saussele
09.55	Q & A session	Panel
10.15	Clinical case presentations 3 & 4	TBD*
<b>10.35</b>	<b>REFRESHMENT BREAK</b>	

**Session 3: Second-line treatment approaches in CML – Tuesday May 18th**

11.00	Unsatisfactory response to first line treatment: second line option of treatment	G. Martinelli
11.20	New generation TK inhibitors in front-line therapy	F. Pane
11.40	Updated ELN recommendations for the management of CML	R. Hehlmann
12.00	Clinical cases 5 & 6	TBD*
12.20	Translational research in the chronic myeloproliferative disorders: the forthcoming pharmaceutical agents	A. Covelli
12.40	Closing address: EUTOS for CML - an innovative collaboration between ELN and Novartis	R. Hehlmann

**13.00****CLOSE**

\*Clinical cases will be prepared and discussed by the members of Faculty

List of speakers:

A. Covelli  
R. Hehlmann  
A. Hochhaus  
L. Luciano  
G. Martinelli  
D. Niederwieser  
F. Pane  
G. Rosti  
G. Saglio  
S. Saussele  
F.X. Mahon